Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arqit Quantum Inc (ARQQ) vs Revvity Inc (RVTY) Price & Performance

Arqit Quantum IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Arqit Quantum Inc vs Revvity Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 30.4× Arqit Quantum Inc's market cap, and Revvity Inc pays a 0.24% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.

ARQQRVTY
Market Cap
$424.79M$12.91B
Sector
TechnologyTechnology
52-Week High
$58.27$117.75
52-Week Low
$11.78$82.26
Enterprise Value
$398.10M$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arqit Quantum Inc

ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.

Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY